BIIB019 (Daclizumab High Yield Process)

BIOLOGICAL3 trials

Sponsors

Biogen

Conditions

Relapsing-Remitting Multiple Sclerosis

Phase 2

Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis

CompletedNCT00390221

BiogenRelapsing-Remitting Multiple Sclerosis

Start: 2008-02-29End: 2011-08-31Updated: 2016-07-11

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis

CompletedNCT00870740

BiogenRelapsing-Remitting Multiple Sclerosis

Start: 2009-02-28End: 2012-10-31Updated: 2016-08-30

Phase 3

Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis

CompletedNCT01064401

BiogenRelapsing-Remitting Multiple Sclerosis

Start: 2010-05-31End: 2014-07-31Updated: 2016-07-11

Related Papers

Longitudinal Changes in Cognitive Test Scores in Patients With Relapsing-Remitting Multiple Sclerosis: An Analysis of the DECIDE Dataset.

2023-04-1820 citations

Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination

Therapeutic Advances in Neurological Disorders2021-01-016 citations

Improved cognitive outcomes in patients with relapsing–remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study

Multiple Sclerosis Journal2017-05-0944 citations

Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis

Multiple Sclerosis and Related Disorders2016-11-1312 citations

Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program.

2016-07-1314 citations

Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis.

2016-06-0123 citations

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis

New England Journal of Medicine2015-10-08258 citations

Results of DECIDE: DAC HYP Superior to IFN- -1a for RRMS

MD Conference Express2014-06-01

DECIDE: Significantly Improved Brain MRI Results with DAC HYP versus Interferon in RRMS

MD Conference Express2014-06-01

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial.

2014-03-1969 citations

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.

2013-04-04205 citations